Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03333616
Title Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

germ cell cancer

penile cancer

urinary bladder cancer

adrenocortical carcinoma

urinary system cancer

prostate cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.